PMID- 21693302
OWN - NLM
STAT- MEDLINE
DCOM- 20111014
LR  - 20220318
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 43
IP  - 5
DP  - 2011 Jun
TI  - Basiliximab for the treatment of steroid-refractory acute graft-versus-host 
      disease after unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell 
      transplantation.
PG  - 1928-33
LID - 10.1016/j.transproceed.2011.03.044 [doi]
AB  - BACKGROUND: Anti-CD(25) monoclonal antibodies (Mabs) have been evaluated for the 
      treatment of steroid-refractory acute graft-versus-host disease (GVHD) in 
      patients undergoing hematopoietic stem cell transplantation (HSCT) mainly with 
      matched donors for years, but there is little attention concerning patients with 
      unmanipulated human leukocyte antigen (HLA)-mismatched/haploidentical 
      transplantations. We investigated the efficacy and safety of the chimeric Mab, 
      basiliximab, to treat steroid-refractory acute GVHD after unmanipulated 
      mismatched/haploidentical HSCT. METHODS: Fifty-three patients who developed 
      steroid-refractory acute GVHD between July 2005 and July 2009 were treated at our 
      institute with basiliximab. No prisoners were used in this study. RESULTS: 
      Forty-six among 53 patients responded, including 37 complete remissions at a 
      median response of 6 days from Mab initiation. There were 29 episodes of viral 
      reactivations, 25 bacterial infections, and 11 probable fungal infections. 
      Thirty-four out of 49 patients who could be evaluated developed chronic GVHD. 
      Twenty-eight of 53 subjects (52.8%) were alive at a median follow-up of 16 months 
      (range, 2-57) posttransplantation. The Kaplan-Meier probability of a 3-year 
      event-free survival was 47.7%. The causes of death were infection alone (n = 15), 
      progressive GVHD with infection (n = 3), relapse (n = 3), and other etiologies (n 
      = 4). CONCLUSION: These data suggested that basiliximab was effective to treat 
      steroid-refractory acute GVHD after unmanipulated HLA-mismatched/haploidentical 
      stem cell transplantation.
CI  - Copyright (c) 2011 Elsevier Inc. All rights reserved.
FAU - Wang, J Z
AU  - Wang JZ
AD  - Peking University People's Hospital, Institute of Hematology, Beijing, China.
FAU - Liu, K Y
AU  - Liu KY
FAU - Xu, L P
AU  - Xu LP
FAU - Liu, D H
AU  - Liu DH
FAU - Han, W
AU  - Han W
FAU - Chen, H
AU  - Chen H
FAU - Chen, Y H
AU  - Chen YH
FAU - Zhang, X H
AU  - Zhang XH
FAU - Zhao, T
AU  - Zhao T
FAU - Wang, Y
AU  - Wang Y
FAU - Huang, X J
AU  - Huang XJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 9927MT646M (Basiliximab)
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Basiliximab
MH  - Child
MH  - Female
MH  - Graft vs Host Disease/diagnosis/*drug therapy
MH  - *Haplotypes
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - *Histocompatibility Testing
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Infections/complications
MH  - Male
MH  - Middle Aged
MH  - Recombinant Fusion Proteins/*therapeutic use
MH  - Retrospective Studies
MH  - Young Adult
EDAT- 2011/06/23 06:00
MHDA- 2011/10/15 06:00
CRDT- 2011/06/23 06:00
PHST- 2010/05/31 00:00 [received]
PHST- 2011/02/27 00:00 [revised]
PHST- 2011/03/15 00:00 [accepted]
PHST- 2011/06/23 06:00 [entrez]
PHST- 2011/06/23 06:00 [pubmed]
PHST- 2011/10/15 06:00 [medline]
AID - S0041-1345(11)00483-0 [pii]
AID - 10.1016/j.transproceed.2011.03.044 [doi]
PST - ppublish
SO  - Transplant Proc. 2011 Jun;43(5):1928-33. doi: 10.1016/j.transproceed.2011.03.044.